ATRA vs NMTC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and financial distress. Despite a current price of $5.22 appearing low relative to an intrinsic value estimate of $20.02, the company exhibits alarming fundamentals including negative operating margin (-102.72%), collapsing revenue (YoY growth: -91.40%), and a bearish insider selling trend. While recent earnings surprises have been positive, the long-term financial instability, lack of reliable Altman Z-Score, and deteriorating cash position overshadow any valuation appeal. The stock's technical trend is deeply bearish, and analyst consensus is only a 'hold' with limited coverage, further undermining confidence.
NMTC presents a contradictory profile with a stable Piotroski F-Score of 6/9 and a very strong liquidity position (Current Ratio 6.41), yet it suffers from severe operational decay. The company is experiencing negative revenue growth (-11.70% YoY) and deep losses, evidenced by an ROE of -146.27%. While the balance sheet is clean with minimal debt (D/E 0.04), the bearish technical trend and consistent lack of profitability make it a high-risk speculative play.
Compare Another Pair
Related Comparisons
ATRA vs NMTC: Head-to-Head Comparison
This page compares Atara Biotherapeutics, Inc. (ATRA) and NeuroOne Medical Technologies Corporation (NMTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.